Activation of HIF-1 by metallothionein contributes to cardiac protection in the diabetic heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 12, 2012, Pages 2528-2535

  Xue, Wanli ^a,b,d   Liu, Yanlong ^a,d   Zhao, Jingchan ^c,d   Cai, Lu ^d   Li, Xiaokun ^a   Feng, Wenke ^a,d  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c NORTHWEST UNIVERSITY   (China)

^d University of Louisville School of Medicine   (United States)

Author keywords

Diabetes; Hypoxia inducible factor

Indexed keywords

BETA ACTIN; GLUCOSE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METALLOTHIONEIN; ZINC;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLYCOLYSIS; HEART INJURY; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOLYSIS; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; METALLOTHIONEIN; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; UP-REGULATION;

EID: 84862508570     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00850.2011     Document Type: Article

References (45)

1. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metform in reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48: 198-202, 1999.
2. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998, 1998.
3. Boudina S, Bugger H, Sena S, O'Neill BT, Zaha VG, Ilkun O, Wright JJ, Mazumder PK, Palfreyman E, Tidwell TJ, Theobald H, Khali-monchuk O, Wayment B, Sheng X, Rodnick KJ, Centini R, Chen D, Litwin SE, Weimer BE, Abel ED. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119: 1272-1283, 2009.
4. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, Kang YJ. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54: 1829-1837, 2005.
5. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by metallothionein of early cardiac cell death via suppression of mito-chondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48: 1688-1697, 2006.
6. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1a protein stability and function. Diabetes 53: 3226-3232, 2004.
7. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brown-lee M, Gurtner GC. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283: 10930-10938, 2008.
8. Chen JX, Stinnett A. Ang-1 gene herapy inhibits hypoxia-Inducible factor-1a (HIF-1a)-prolyl-4-hydroxylase-2, stabilizes HIF-1a expression, and normalizes immature vasculature in db/db mice. Diabetes 57: 3335-3343, 2008.
9. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105: 373-379, 2002.
10. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci 59: 627-647, 2002.
11. England K, O'Driscoll C, Cotter TG. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ 11: 252-260, 2004.
12. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulinlike growth factor 2. Cancer Res 59: 3915-3918, 1999.
13. Feng W, Wang Y, Cai L, Kang YJ. Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions. Biochem Biophys Res Commun 360: 286-289, 2007.
14. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50: 2363-2375, 2001.
15. Gao W, Ferguson G, Connell P, Walshe T, Murphy R, Birney YA, O'Brien C, Cahill PA. High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1a-dependent pathway. J Mol Cell Cardiol 42: 609-619, 2007.
16. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol Cell Physiol 268: C1362-C1368, 1995.
17. Heather LC, Clarke K. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 0: 598-605, 2011.
18. Kang YJ, Cai L. Metallothionein suppression of diabetic cardiomyopathy by inhibition of hyperglycemia-induced oxidative stress. Free Radic Biol Med 31: S33, 2001.
19. Kim HG, Hwang YP, Jeong HG. Metallothionein-III induces HIF-1a-mediated VEGF expression in brain endothelial cells. Biochem Biophys Res Commun 369: 666-671, 2008.
20. Kojima I, Tanaka T, Inagi R, Nishi H, Aburatani H, Kato H, Miyata T, Fujita T, Nangaku M. Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int 75: 268-277, 2009.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-AACt) method. Methods 25: 402-408, 2001.
22. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374, 2004.
23. Meplan C, Richard MJ, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19: 5227-5236, 2000.
24. Murphy BJ, Kimura T, Sato BG, Shi Y, Andrews GK. Metallothionein induction by hypoxia involves cooperative interactions between metal-responsive transcription factor-1 and hypoxia-inducible transcription factor-1a. Mol Cancer Res 6: 483-490, 2008.
25. Murphy BJ, Sato BG, Dalton TP, Laderoute KR. The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxic stress. Biochem Biophys Res Commun 337: 860-867, 2005.
26. Osawa H, Printz RL, Whitesell RR, Granner DK. Regulation of hexokinase II gene transcription and glucose phosphorylation by catecholamines, cyclic AMP, and insulin. Diabetes 44: 1426-1432, 1995.
27. Ren J, Privratsky JR, Yang X, Dong F, Carlson EC. Metallothionein alleviates glutathione depletion-induced oxidative cardiomyopathy in murine hearts. Crit Care Med 36: 2106-2116, 2008.
28. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marce M, Semenza GL. Adenoviral transfer of HIF-1a enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci USA 106: 18769-18774, 2009.
29. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996.
30. Semenza GL, Shimoda LA, Prabhakar NR. Regulation of gene expression by HIF-1. Novartis Found Symp 272: 2-8, 2006.
31. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
32. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1a, HDM2, and p70S6K1 in Response to phosphatidyl-inositol 3-kinase/AKT signaling. J Biol Chem 279: 45643-45651, 2004.
33. Thangarajah H, Vial IN, Grogan RH, Yao D, Shi Y, Januszyk M, Galiano RD, Chang EI, Galvez MG, Glotzbach JP, Wong VW, Brownlee M, Gurtner GC. HIF-1a dysfunction in diabetes. Cell Cycle 9: 75-79, 2010.
34. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106: 13505-13510, 2009.
35. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276: 43836-43841, 2001.
36. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
37. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308, 1993.
38. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113: 544-554, 2006.
39. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN. Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. Am J Physiol Heart Circ Physiol 294: H2889-H2897, 2008.
40. Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L. Inactivation of GSK-3fj by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 58: 1391-1402, 2009.
41. 2+ cycling proteins, NADPH oxidase, poly(ADP-ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 40: 1419-1429, 2006.
42. Xue W, Cai L, Tan Y, Thistlethwaite P, Kang YJ, Li X, Feng W. Cardiac-specific overexpression of HIF-1a prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice. Am J Pathol 177: 97-105, 2010.
43. Xue W, Liu Q, Cai L, Wang Z, Feng W. Stable overexpression of human metallothionein-IIA in a heart-derived cell line confers oxidative protection. Toxicol Lett 188: 70-76, 2009.
44. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52: 777-783, 2003.
45. Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, Cai L. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 52: 655-666, 2008.